What Are Genomic Alerts in EHRs?
A growing number of U.S. health systems are now embedding genomic alerts directly into their electronic health records (EHRs). These alerts notify clinicians about actionable genetic variants that may affect a patient’s response to medication. Instead of relying on static PDF reports buried in a chart, providers now receive real-time, structured decision support at the point of care.
This shift marks a significant turning point. Traditionally, genomic data lived outside the clinical workflow—locked in specialty lab reports or scanned documents. Today, structured integration makes that data computable, searchable, and actionable.
Why 10 Health Systems Are Leading the Shift
Ten health systems have now implemented genomic clinical decision support (CDS) alerts within their EHR platforms. This milestone reflects years of collaborative work between precision medicine teams, informatics specialists, and clinical pharmacists.
The Move Away From PDF-Based Genomic Reporting
For years, most genomic test results reached clinicians as unstructured text files or PDF reports. Those formats made it nearly impossible to trigger automated alerts or cross-reference variants across a patient’s care history. As one genomics expert noted, a PDF-based result simply cannot drive clinical decision-making at scale—structured data can.
Epic’s Genomic Module as a Catalyst
Several of these 10 systems use Epic’s Genomic Module, which introduced a new variant database and genomic indicators. These tools flag actionable genetic information directly within the EHR workflow. Consequently, clinicians can access gene-drug interaction alerts right when they prescribe a medication—without consulting separate systems or specialty consultants.
How Genomic CDS Alerts Work in Practice
Genomic CDS alerts rely on structured pharmacogenomic data interfaced from clinical labs using HL7 standards. When a clinician orders a medication, the EHR’s CDS engine checks the patient’s genomic profile and surfaces a relevant alert if a drug-gene interaction exists.
Real-World Alert Examples
- A patient carrying the HLA-B*57:01 allele receives an alert warning against abacavir, a common HIV medication.
- A clinician prescribing simvastatin is notified when the patient carries an SLCO1B1 variant linked to statin-induced muscle damage.
- Voriconazole dosing adjustments are flagged for patients with CYP2C19 metabolizer variants.
From Interruptive to Ambient Alerts
Early implementations used interruptive pop-up alerts that interrupted workflows. Newer approaches use non-interruptive, ambient notifications that surface genomic data in context—reducing alert fatigue while keeping clinicians informed.
Key Benefits for Clinicians and Patients
Embedding genomic alerts into EHRs delivers clear advantages across the care continuum. Moreover, these benefits compound over time as more patients receive genomic testing and results populate the system.
For clinicians, CDS alerts provide just-in-time knowledge about drug-gene interactions that most prescribers would not otherwise know. Furthermore, they reduce the need for manual chart review or specialist referrals for routine prescribing decisions.
For patients, genomic alerts reduce the risk of adverse drug reactions. They also support truly personalized prescribing—matching the right drug and dose to an individual’s genetic profile rather than relying on population-level averages.
For health systems, structured genomic data enables research, quality improvement, and population health analysis. Additionally, systems can track prescribing patterns and measure the real-world impact of CDS interventions.
Challenges That Still Need Addressing
Despite the progress, significant hurdles remain. Not every health system has the informatics infrastructure, personnel, or funding to implement genomic CDS at scale.
Alert Fatigue Remains a Concern
Too many alerts create noise. Clinicians often override alerts without reading them—a phenomenon known as alert fatigue. Therefore, thoughtful curation of which genomic alerts truly warrant interruption is critical. Systems must balance completeness with clinical relevance.
Standardization Gaps Persist
Variation in EHR systems, lab data formats, and institutional workflows makes it difficult to share alert data or benchmark performance across sites. As a result, each health system often builds custom solutions from the ground up. National efforts, including CPIC guidelines and FHIR-based interoperability standards, are helping close this gap. However, widespread adoption still takes time.
Clinician Education Lags Behind Technology
Many prescribers lack foundational training in pharmacogenomics. Even when alerts appear on screen, clinicians may not know how to interpret or act on them effectively. Consequently, implementation must pair technology rollout with targeted education programs.
What This Means for the Future of Precision Medicine
The expansion of genomic alerts to 10 health systems signals that genomics is moving from the research lab into routine clinical practice. This transition, however, is just the beginning.
Scaling Across Community and Rural Systems
Most early adopters have been large academic medical centers. The next frontier involves extending these capabilities to community hospitals and rural health systems—settings where specialist access is limited and clinical decision support could have the greatest impact.
Beyond Pharmacogenomics
While drug-gene interaction alerts dominate current implementations, the same infrastructure can eventually support alerts for hereditary disease risk, cancer screening recommendations, and population-level variant surveillance. Thus, the groundwork being laid today will support far broader precision medicine applications tomorrow.
The integration of genomic alerts into EHRs across 10 health systems demonstrates that precision medicine is becoming a clinical reality. As interoperability standards mature and EHR vendors invest further in genomic modules, more systems will follow—bringing personalized, genetically informed care to a far wider patient population.
